Zelmic continues to expand its capabilities in advanced topical and transdermal drug development with a strategic investment in state-of-the-art analytical instrumentation: the Vanquish™ Horizon UHPLC System (integrated biocompatible system). This investment marks an important step in supporting the growing demand for oligonucleotide-based therapeutics, including siRNA and other nucleic acid modalities. Enabling the Next Generation of…
As 2025 comes to a close, we at Zelmic AB would like to extend our sincere thanks to our clients, collaborators, and partners for a truly remarkable year. This year has been a period of innovation and transformation in topical and transdermal drug development. Together, we have continued to advance projects that push the boundaries…
Zelmic is proud to announce the continued and expanded collaboration with TIRmed Pharma in the development of TIR-C, a novel topical oligonucleotide-based treatment for atopic dermatitis. This innovative drug candidate is designed to address the underlying causes of the disease, not just its symptoms, and has shown highly promising preclinical results — with five topical…
Next week on the 13th of october, the Zelmic team will participate in Nordic Life Science Days (NLSDays) 2025 in Gothenburg — the Nordic region’s largest partnering event for the life science community. We look forward to meeting innovators, biotech entrepreneurs, and pharma partners to discuss the latest developments in topical and transdermal drug delivery,…
Understanding the regulatory boundary and how Zelmic supports cosmetic brands The line between cosmetics and medicinal products is not always clear, especially in the field of skin formulations. For companies developing innovative creams, gels, or serums, understanding this distinction is critical. Cosmetics vs. Medicinal Products – the Regulatory Difference A cosmetic product is intended to…
As we head into the summer months, we want to take a moment to share some exciting updates from our team at Zelmic. New license We’ve reached two important milestones. We’ve obtained our MIA license, where we can help clients with imports from third countries, allowing us to manage global supply chains more efficiently and…
In the development of topical drug formulations, one of the greatest challenges is ensuring that in vitro (laboratory-based) tests accurately reflect how a drug will behave in vivo (on human skin). This is where In Vitro-In Vivo Correlation (IVIVC) plays a crucial role. A strong IVIVC allows pharmaceutical developers to predict drug absorption, efficacy, and…
Winter may have surrounded us in darkness, but here at Zelmic, we’re seeing the light – in the form of new opportunities and exciting projects for 2025! After a well-deserved winter break, we’re back, energized, and ready to continue driving innovation and excellence in topical product development, analytical chemistry, in vitro models, and IMP manufacturing…
We are excited to announce that Zelmic will be exhibiting at this year’s NLSdays (Nordic Life Science Days) in Malmö! As one of the leading events in the Nordic region, NLSdays brings together key players in the life science sector, and we’re thrilled to be a part of it again this year. Visit Us at…
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK
